Sean G. Buchanan BA, PhD

Dr. Sean Buchanan is a Research Fellow leading a preclinical Translational Oncology group at Eli Lilly & Co. based in Indianapolis, Indiana, USA. He earned a BA and PhD at Cambridge University in the UK, and in 1999 joined SGX Pharmaceuticals in San Diego, California as a founding scientist where he led the Oncology Biology department. Dr Buchanan joined Eli Lilly in 2008 and set up a translational research group for oncology in 2010. He has overseen the introduction of pharmacogenomics and synthetic lethal shRNA and CRISPR screening platforms at Eli Lilly and is also the lead preclinical scientist for Lilly’s CDK4/6 inhibitor abemaciclib.